# A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB

> **NCT02430506** · PHASE1 · COMPLETED · sponsor: **Aeras** · enrollment: 20 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** AERAS-402

## Key facts

- **NCT ID:** NCT02430506
- **Lead sponsor:** Aeras
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2009-06
- **Final completion:** 2010-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02430506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02430506, "A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02430506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*